Loose Skin After GLP-1 Weight Loss: What GHK-Cu and GLOW Can and Cannot Do, According to the Evidence

Ask this question in any weight-loss or peptide community and the reply comes fast: try GHK-Cu, or try GLOW. The question is fair, because massive weight loss is associated with documented dermal changes and imaging of GLP-1 users shows midfacial volume loss, and GHK-Cu has a long research trail in dermal biology. What nobody in those threads has is a study: no clinical trial has tested GHK-Cu, GLOW or KLOW on loose skin after weight loss, in any population, at any dose. This article lays out what the histology and imaging literature has documented about post-weight-loss skin, what GHK-Cu has actually shown in the studies that exist, and where the evidence stops and the marketing language starts.

What people are asking

Community threads about loose skin after GLP-1-class weight loss are a recurring theme in the research-peptide corner of Reddit. Across r/Peptides, r/Biohackers, r/PeptideDiscussion, r/Retatrutide, r/tirzepatidecompound, r/Semaglutide and r/BPC157, over the 12 months to August 2026, 1,141 posts discuss loose or sagging skin, skin laxity, "Ozempic face," crepey skin, excess skin, elasticity, wrinkles or collagen. Of those, 253 also mention GHK-Cu, GLOW, KLOW, BPC-157 or TB-500 by name, which is the subset this article is really about. The community layer here is Reddit only; YouTube content was not reviewed.

Where those 253 posts originate: r/Peptides 75, r/Biohackers 73, r/Retatrutide 59, r/PeptideDiscussion 38, r/tirzepatidecompound 7, r/Semaglutide 1.

Eleven threads illustrate the pattern. "Best peptide for loose skin" (18 upvotes, 46 comments) is a retatrutide user asking whether GHK-Cu will help abdominal skin. "Is ghk-cu for tightening loose skin? Or should I have gotten something else." (16 upvotes) asks the same question from the other direction. "GHK-Cu vs Glow vs Klow" (20 upvotes) frames the choice around recovery, general health, wrinkles and some loose skin. "Looking at KLOW for aging skin benefits" (40 upvotes) is a 51-year-old asking about lower-face laxity. "GLOW: Loose skin, tattoos, etc" (11 upvotes) is a 24-year-old after a 70 lb loss with mild loose skin and stretch marks, asking whether time alone will do the job. "Can we talk about loose skin" (14 upvotes) describes 60 lb lost, loose abdominal skin, a GLOW vial just started alongside red light therapy and moisturizer, and asks whether anything besides surgery worked. "6 month Reta update do I need surgery?" (26 upvotes) went from 128 kg to 91 kg and asks about avoiding a tummy tuck. "14 Weeks, 23kg, Ask about Loose Skin" (35 upvotes) asks the same question after a 23 kg loss. "Ghkcu 2 weeks in" (44 upvotes) reports skin compliments after two weeks, but the poster also started collagen powder, vitamin C and zinc at the same time, which makes attributing the result to any single input impossible. "Ghk cu is underrated" (26 upvotes, 85 comments) lists claimed benefits without sources, and "What was your experience with GHK-cu?" (14 upvotes, 58 comments) collects more of the same.

The pattern across all of them: claimed results are self-reports, usually with several interventions started together, a collagen supplement, red light, training, the weight-loss drug itself, with no before-and-after measurement and no control group. The four posts reporting no effect are just as unverifiable as the 66 reporting a noticed result; neither is evidence of anything beyond what one person believed happened.

What fast weight loss does to skin

Before asking what a peptide might do, it helps to know what the weight loss itself does. Three histomorphometric studies in massive-weight-loss cohorts (two purely post-bariatric, one comparing surgical and non-surgical weight loss) describe the same underlying change from different angles.

Orpheu's own description is direct: patients "displayed lax, soft skin lacking sufficient collagen fiber network," while elastic fiber content "was not damaged, and was even moderately increased in epigastrium." Collagen loss is the constant across all three studies; elastin behaves inconsistently, preserved or increased in Orpheu and Rocha, lower in the surgical group of Hany. The structural protein most consistently lost after massive weight loss is collagen.

Imaging tells a parallel story in the face. Sharma et al. 2025 followed 20 patients on GLP-1 agonists with CT or MRI before and after treatment (2017-2024), median age 54, average treatment 321 days, average weight loss 11.0 kg. Median total midfacial volume fell 9.0% (IQR 3-14%), with superficial fat down 11.0% and deep fat down 7.0%. Superficial volume loss correlated with weight loss (rho 0.590, P=.006); deep volume loss did not. The authors' own regression works out to roughly 7% of midfacial volume lost per 10 kg of weight loss, concentrated in the superficial fat pads, and they describe the study as one of the first quantitative assessments of "Ozempic face."

A 2025 systematic review by Daneshgaran et al., in Aesthetic Surgery Journal Open Forum, puts the evidence behind that term in context: 23 articles, 96% published in 2023-2025 (5 correspondence pieces, 5 reviews, 4 case reports, 3 retrospective cohorts, 2 viewpoints, 2 special focus articles, one survey, one systematic review), and not a single randomized trial. Its conclusion is blunt: "Evidence to suggest that GLP-1 receptor agonists preferentially result in facial fat atrophy is lacking." The same review notes that these effects "are more pronounced in older individuals with naturally lower levels of collagen," and reports that some authors read the phenomenon as GLP-1 drugs accentuating an age-related decline in elastin turnover that was already present, revealed by a thinner fat layer rather than caused underneath it.

A separate 2025 review in Endocrine, by Paschou et al., proposes mechanisms beyond simple fat loss. GLP-1 receptors sit on adipose-derived stem cells and on fibroblasts; in their model, receptor stimulation reduces the ability of those stem cells to produce protective cytokines, promotes reactive oxygen species and oxidative damage to fibroblasts, and reduces glucose uptake, leading to lower ATP production and apoptosis. The review also proposes an indirect route: reduced estrogen production from dermal white adipose tissue, which lowers the stimulus for fibroblasts to produce collagen, plus a possible interaction with the AGE/RAGE pathway. The authors frame it carefully: the complication "is not exclusively related to decreased facial fat, but there are more aging mechanisms that have to be elucidated." This is cell-culture and mechanistic reasoning, not a biopsy of human skin taken during GLP-1 therapy.

The cell data do not point only one way. Anastasiou et al. 2025, working in vitro, treated human dermal fibroblasts with semaglutide (0 to 45 pg/mL for 24 hours) under hydrogen-peroxide oxidative stress and reported protective, wound-healing-promoting effects in the dish, the opposite direction from Paschou's oxidative-damage model, in a comparable in vitro system. The honest reading is that no mechanism is settled: the same drug class looks damaging in one model and protective in another.

One 2026 study shows what an actual intervention trial in this population looks like. Nguyen et al. followed 33 adults with rapid weight loss, mostly from GLP-1/GIP agonists, using a single topical "volumizing" cream for 12 weeks; 29 completed it, with no control group. By week 12, wrinkle severity was down 20.7% (14.5% at week 4), ultrasound-measured skin-plus-subcutaneous thickness was up 20.1% (17.3% at week 4), firmness was up 22.5% and net elasticity up 23.2%. Read this less for the specific cream than for the endpoints it used, cutometry-style firmness and elasticity, ultrasound thickness, wrinkle-severity assessment, and for the honest limit: a single-arm, sponsor-product study cannot separate the cream's effect from skin remodeling that would have happened anyway over the same 12 weeks.

What GHK-Cu has actually shown on skin

GHK-Cu has a real, decades-long research trail, just not one that touches loose skin after weight loss.

The earliest relevant finding is Maquart et al. 1988: GHK-Cu stimulates collagen synthesis in cultured fibroblasts, a cell-dish result. The central in vivo study is Maquart et al. 1993, a rat wound-chamber model: stainless-steel mesh cylinders were implanted under the skin, then injected repeatedly with GHK-Cu or saline. GHK-Cu produced a concentration-dependent increase in dry weight, DNA, total protein, collagen and glycosaminoglycans inside the chamber; collagen synthesis was stimulated about twice as much as non-collagen protein synthesis; type I and III collagen mRNA rose while TGF-beta mRNA did not; a control tripeptide had no effect at all. This is a real and specific result, injected GHK-Cu, in an artificial wound chamber, in rats. It is not a study of intact loose skin, and it is not in humans.

The closest thing to a controlled human trial is Miller et al. 2006, a randomized study of topical GHK-Cu skin care after CO2 laser resurfacing, with 13 completers. Objective measurement found no significant difference in erythema resolution and, in the authors' words, "no significant improvement in wrinkles or overall skin quality." The one measure that did move was subjective: patient satisfaction was significantly higher with GHK-Cu (P=.04). That gap, between what patients felt and what the instruments measured, is worth sitting with.

The most widely repeated claim comes from Pickart et al. 2015, a review stating that "in cosmetic products, it has been found to tighten loose skin and improve elasticity, skin density, and firmness, reduce fine lines and wrinkles." That sentence summarizes cosmetic-industry studies of topical formulations, largely never published as controlled, peer-reviewed trials, an industry summary, not the same evidence tier as Maquart's or Miller's data. A 2025 review by Mortazavi et al. reaches a blunter conclusion about topical GHK: published information on its skin permeability, effectiveness and physicochemical properties "is insufficient."

Our PubMed check in August 2026 found no study of GHK-Cu, by any route, in skin after weight loss; searches combining "GHK" with "weight loss," "skin laxity" or "loose skin" return nothing. How GHK-Cu's route of administration, topical versus injected, affects penetration, and where it sits regulatorily, is covered in full in our route comparison; this article does not repeat that ground.

GLOW and KLOW: three rationales, no test

GLOW is sold as a blend with a labeled total of 70 mg: 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg full-length thymosin beta-4 (TB-500). KLOW adds 10 mg KPV, for a labeled 80 mg total. No study compares the two blends head-to-head, and no study, of any design, tests either blend at all.

Thymosin beta-4, the active studied under the TB-500 name, has a real wound-healing literature. Kleinman and Sosne's 2016 review describes it increasing the rate of dermal healing in preclinical models, including diabetic and aged animals and burns, and reports that it "accelerated the rate of repair in phase 2 trials with patients having pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds." That is wound repair, a damaged-skin, closing-a-defect endpoint. It is not a skin-laxity or tightening endpoint, and it was not tested in intact skin left loose by weight loss.

BPC-157 has no skin-laxity or dermal-collagen data in humans at all; its literature is preclinical wound and tendon healing. There is no citation to give for a laxity claim because none exists.

Put together, a blend like GLOW or KLOW stacks three separate preclinical rationales, collagen synthesis in a rat wound chamber, dermal wound-healing in diabetic and aged animal models, and a component with no human skin-laxity or dermal-collagen data, without anyone having tested the combination, or any one component, on loose skin after weight loss. A full composition and evidence comparison across GLOW, KLOW and WOLVERINE is in our blend comparison; the buying guide for GLOW, including its lab report, is here.

The gap, stated plainly

None of this means the question is unanswerable, only that it has not been answered yet. The field already has the tools: cutometry for firmness and net elasticity, high-frequency ultrasound for dermal thickness, transepidermal water loss, standardized photography, and, where biopsies are ethically justified, histology of the kind used in the three bariatric studies above. The 2026 cream study described earlier is a small-scale example of exactly that toolkit applied in a comparable population.

What none of the current data has is a control. Skin retracts and remodels on its own over the months after weight stabilizes, and self-reports in the community almost always involve several concurrent interventions, a collagen supplement, red light, training, the weight-loss drug itself. Without a comparison group that is not taking GHK-Cu, GLOW or KLOW, and without a documented starting measurement, no self-report, however consistent it sounds across many threads, can separate a peptide's effect from time.

What the aesthetic literature discusses instead

Absent peptide data, the aesthetic-medicine literature discusses other interventions for post-weight-loss skin changes: fillers, biostimulators, energy-based devices, and, for larger amounts of excess skin, surgery. Haykal et al. 2025 and Bariskan et al. 2026 both describe this landscape while explicitly flagging "gaps in empirical data" and uncertainty over "optimal timing for interventions," and call for research into "the molecular mechanisms behind collagen degradation, fat loss, and skin elasticity." That is a call for more study, not a settled protocol.

Two qualifiers recur in that literature. Age: the effect is "more pronounced in older individuals with naturally lower levels of collagen." Timing: assessment of skin, and of any intervention, is generally discussed as something to defer until weight has stabilized, since the skin is still remodeling while weight is still changing. Neither point is a recommendation from us; both are what the field itself discusses.

Where these products sit in our catalog

None of the above changes what GHK-Cu, GLOW and KLOW are as research materials, only what can honestly be claimed for them on the specific question of loose skin after weight loss.

Frequently asked questions

Sources

1. Orpheu SC, et al. Collagen and elastic content of abdominal skin after surgical weight loss. Obes Surg. 2010. PMID 19937152. https://pubmed.ncbi.nlm.nih.gov/19937152/
2. Rocha RI, et al. Skin Changes Due to Massive Weight Loss: Histological Changes and the Causes of the Limited Results of Contouring Surgeries. Obes Surg. 2021. PMID 33145720. https://pubmed.ncbi.nlm.nih.gov/33145720/
3. Hany M, et al. Comparison of Histological Skin Changes After Massive Weight Loss in Post-bariatric and Non-bariatric Patients. Obes Surg. 2024. PMID 38277086. https://pubmed.ncbi.nlm.nih.gov/38277086/
4. Sharma RK, et al. Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists. Otolaryngol Head Neck Surg. 2025. PMID 40407186. https://pubmed.ncbi.nlm.nih.gov/40407186/
5. Daneshgaran G, et al. "Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions. Aesthet Surg J Open Forum. 2025. PMID 40626110. https://pubmed.ncbi.nlm.nih.gov/40626110/
6. Paschou IA, et al. GLP-1RA and the possible skin aging. Endocrine. 2025. PMID 40498168. https://pubmed.ncbi.nlm.nih.gov/40498168/
7. Anastasiou IA, et al. Semaglutide Enhances Cellular Regeneration in Skin and Retinal Cells In Vitro. Pharmaceutics. 2025. PMID 41012453. https://pubmed.ncbi.nlm.nih.gov/41012453/
8. Nguyen N, et al. Topical Volumizing Cream Improves Facial Volume and Skin Health in Adults With Rapid Weight Loss From Pharmacologic (GLP-1/GIP Agonists), Surgical, or Behavioral Interventions. J Cosmet Dermatol. 2026. PMID 41556403. https://pubmed.ncbi.nlm.nih.gov/41556403/
9. Haykal D, et al. The Role of GLP-1 Agonists in Esthetic Medicine: Exploring the Impact of Semaglutide on Body Contouring and Skin Health. J Cosmet Dermatol. 2025. PMID 39645647. https://pubmed.ncbi.nlm.nih.gov/39645647/
10. Bariskan S, et al. Losing Weight and Gaining Wrinkles: The Impact of Weight Loss Drugs on Facial Aesthetics. J Craniofac Surg. 2026. PMID 41842736. https://pubmed.ncbi.nlm.nih.gov/41842736/
11. Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988. PMID 3169264. https://pubmed.ncbi.nlm.nih.gov/3169264/
12. Maquart FX, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993. PMID 8227353. https://pubmed.ncbi.nlm.nih.gov/8227353/
13. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. PMID 16847171. https://pubmed.ncbi.nlm.nih.gov/16847171/
14. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015. PMID 26236730. https://pubmed.ncbi.nlm.nih.gov/26236730/
15. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts. 2025. PMID 39963574. https://pubmed.ncbi.nlm.nih.gov/39963574/
16. Kleinman HK, Sosne G. Thymosin beta4 Promotes Dermal Healing. Vitam Horm. 2016. PMID 27450738. https://pubmed.ncbi.nlm.nih.gov/27450738/
17. Reddit corpus extraction, 12 months to August 2026 (our own count: 1,141 skin-laxity posts, 253 mentioning the peptides named above); threads cited by title, not linked.
18. PeptidesDirect product documentation for GLOW and KLOW (labelled composition), /products/glow and /products/klow.

Research use only. GHK-Cu, GLOW and KLOW are supplied for laboratory research, not for human or animal administration, and not as a medicine or cosmetic. Nothing in this article is a dosing, protocol or treatment recommendation.